Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Vanguard Real Estate Index Fund ETF trades at $95.14. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VNQ | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | — |
52-Week High | $6.79 | $100.95 |
52-Week Low | $2.84 | $87.00 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
VNQ trades at $95.92, down 0.1% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure while oscillators remain neutral. The ETF faces headwinds from elevated interest rates impacting real estate valuations, though some analysts see mispricing opportunities in quality REITs during this downturn. Recent institutional selling activity and mixed media sentiment reflect ongoing sector challenges.
The outlook remains cautious as high rates pressure REIT valuations, but selective opportunities exist in digital infrastructure and quality names. Key risks include prolonged high interest rates, economic slowdowns affecting property demand, and competition from alternative income ETFs. Investors should focus on REITs with strong fundamentals and growth potential in evolving sectors like AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
